N4BP2L2

Summary

N4BP2L2 (NEDD4 binding protein 2 like 2, HGNC:26916) is a protein-coding gene on chromosome 13q13.1, encoding NEDD4-binding protein 2-like 2 (Q92802).

Enables enzyme binding activity. Involved in negative regulation of hematopoietic stem cell differentiation and positive regulation of hematopoietic stem cell proliferation. Located in nucleus. Part of transcription repressor complex.

Source: NCBI Gene 10443 — RefSeq curated summary.

At a glance

• GWAS associations: 8
• Clinical variants (ClinVar): 42 total — 1 pathogenic
• MANE Select transcript: NM_014887

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26916
Approved symbol	N4BP2L2
Name	NEDD4 binding protein 2 like 2
Location	13q13.1
Locus type	gene with protein product
Status	Approved
Aliases	CG005, PFAAP5
Ensembl gene	ENSG00000244754
Ensembl biotype	protein_coding
OMIM	615788
Entrez	10443

Gene structure

Transcript identifiers

Ensembl transcripts: 52 — 26 protein_coding, 13 retained_intron, 7 protein_coding_CDS_not_defined, 6 nonsense_mediated_decay

ENST00000267068, ENST00000357505, ENST00000380121, ENST00000399396, ENST00000446957, ENST00000473025, ENST00000475731, ENST00000483088, ENST00000503296, ENST00000503814, ENST00000504114, ENST00000505213, ENST00000509076, ENST00000511143, ENST00000512755, ENST00000674161, ENST00000674163, ENST00000674180, ENST00000674196, ENST00000674219, ENST00000674272, ENST00000674276, ENST00000674279, ENST00000674293, ENST00000674297, ENST00000674327, ENST00000674346, ENST00000674349, ENST00000674369, ENST00000674377, ENST00000674384, ENST00000674399, ENST00000674408, ENST00000674421, ENST00000674422, ENST00000674428, ENST00000674433, ENST00000674437, ENST00000674452, ENST00000674456, ENST00000674462, ENST00000674465, ENST00000674480, ENST00000674484, ENST00000674494, ENST00000884184, ENST00000884185, ENST00000884186, ENST00000884187, ENST00000884188, ENST00000946928, ENST00000946929

RefSeq mRNA: 35 — MANE Select: NM_014887 NM_001278432, NM_001320836, NM_001387001, NM_001387002, NM_001387008, NM_001387009, NM_001387015, NM_001387016, NM_001387018, NM_001387019, NM_001387020, NM_001387059, NM_001387060, NM_001387079, NM_001387080, NM_001387081, NM_001387082, NM_001387083, NM_001387099, NM_001387100, NM_001387101, NM_001387102, NM_001387103, NM_001387104, NM_001387105, NM_001387106, NM_001387107, NM_001387108, NM_001387165, NM_001387223, NM_001387224, NM_001387225, NM_001395224, NM_014887, NM_033111

CCDS: CCDS45024, CCDS61307, CCDS91796, CCDS91797, CCDS91798, CCDS91799, CCDS9346

Canonical transcript exons

ENST00000267068 — 6 exons

Exon	Start	End
ENSE00002039054	32521373	32521449
ENSE00003500014	32522182	32522270
ENSE00003628457	32527408	32527532
ENSE00003667303	32510292	32518003
ENSE00003755930	32535769	32537027
ENSE00003978141	32538618	32538795

Expression profiles

Bgee: expression breadth ubiquitous, 301 present calls, max score 99.48.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 60.5511 / max 1845.3212, expressed in 1812 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
136715	51.8627	1801
136714	5.3262	1474
136716	2.1882	909
136713	0.8175	428
136712	0.3564	126

Top tissues by expression

301 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
calcaneal tendon	UBERON:0003701	99.48	gold quality
choroid plexus epithelium	UBERON:0003911	99.14	gold quality
nipple	UBERON:0002030	98.76	gold quality
tendon	UBERON:0000043	98.74	gold quality
cardia of stomach	UBERON:0001162	98.42	gold quality
renal medulla	UBERON:0000362	98.22	gold quality
colonic epithelium	UBERON:0000397	98.22	gold quality
endothelial cell	CL:0000115	98.17	gold quality
germinal epithelium of ovary	UBERON:0001304	98.09	gold quality
pylorus	UBERON:0001166	98.05	gold quality
parotid gland	UBERON:0001831	97.99	gold quality
urethra	UBERON:0000057	97.92	gold quality
visceral pleura	UBERON:0002401	97.74	gold quality
seminal vesicle	UBERON:0000998	97.71	gold quality
sural nerve	UBERON:0015488	97.70	gold quality
tendon of biceps brachii	UBERON:0008188	97.66	gold quality
penis	UBERON:0000989	97.64	gold quality
right uterine tube	UBERON:0001302	97.58	gold quality
left ovary	UBERON:0002119	97.58	gold quality
upper leg skin	UBERON:0004262	97.51	gold quality
superficial temporal artery	UBERON:0001614	97.49	gold quality
right ovary	UBERON:0002118	97.44	gold quality
tibia	UBERON:0000979	97.39	gold quality
trabecular bone tissue	UBERON:0002483	97.38	gold quality
corpus callosum	UBERON:0002336	97.36	gold quality
monocyte	CL:0000576	97.35	gold quality
mononuclear cell	CL:0000842	97.33	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	97.31	gold quality
tonsil	UBERON:0002372	97.21	gold quality
adrenal tissue	UBERON:0018303	97.21	gold quality

Single-cell (SCXA)

Detected in 11 experiment(s), a significant marker in 5.

Experiment	Marker?	Max mean expression
E-HCAD-1	yes	29.42
E-CURD-122	yes	20.28
E-MTAB-8142	yes	12.83
E-GEOD-125970	yes	6.65
E-MTAB-8381	no	1307.72
E-GEOD-70580	no	1216.88
E-HCAD-36	no	1124.22
E-CURD-46	no	945.35
E-MTAB-6386	no	717.05
E-HCAD-4	no	77.70
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

70 targeting N4BP2L2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-1252-5P	100.00	69.80	2774
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-548J-3P	99.94	72.61	4881
HSA-MIR-548AE-3P	99.93	72.66	4867
HSA-MIR-548AH-3P	99.93	72.54	4872
HSA-MIR-548AM-3P	99.93	72.54	4872
HSA-MIR-548AQ-3P	99.93	72.66	4867
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-548D-3P	99.87	70.67	4362
HSA-MIR-548BB-3P	99.86	70.58	4354
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-548AC	99.84	70.77	4351
HSA-MIR-548H-3P	99.84	70.80	4349
HSA-MIR-548Z	99.84	70.80	4349
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-3121-3P	99.82	71.96	3630

Literature-anchored findings (GeneRIF, showing 1)

• Data suggest that expression of PFAAP5 allows neutrophil elastase to potentiate the repression of Gfi1 target genes. (PMID:19506020)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	n4bp2l2	ENSDARG00000103507
mus_musculus	N4bp2l2	ENSMUSG00000029655
rattus_norvegicus	N4bp2l2	ENSRNOG00000001108

Paralogs (2): N4BP2 (ENSG00000078177), N4BP2L1 (ENSG00000139597)

Protein

Protein identifiers

NEDD4-binding protein 2-like 2 — Q92802 (reviewed: Q92802)

Alternative names: Phosphonoformate immuno-associated protein 5

All UniProt accessions (17): A0A6I8PL40, A0A6I8PL95, A0A6I8PRE0, A0A6I8PRI0, A0A6I8PRM1, A0A6I8PRP6, A0A6I8PRR0, A0A6I8PRR5, A0A6I8PRT3, A0A6I8PRV3, A0A6I8PRX5, A0A6I8PRY6, A0A6I8PS46, A0A6I8PU16, B4DPY1, D6R968, Q92802

UniProt curated annotations — full annotation on UniProt →

Isoforms (3)

UniProt ID	Names	Canonical?
Q92802-1	1	yes
Q92802-2	2
Q92802-3	3

RefSeq proteins (35): NP_001265361, NP_001307765, NP_001373930, NP_001373931, NP_001373937, NP_001373938, NP_001373944, NP_001373945, NP_001373947, NP_001373948, NP_001373949, NP_001373988, NP_001373989, NP_001374008, NP_001374009, NP_001374010, NP_001374011, NP_001374012, NP_001374028, NP_001374029, NP_001374030, NP_001374031, NP_001374032, NP_001374033, NP_001374034, NP_001374035, NP_001374036, NP_001374037, NP_001374094, NP_001374152, NP_001374153, NP_001374154, NP_001382153, NP_055702, NP_149102 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026302	NEDD4-bd_p2	Family
IPR027417	P-loop_NTPase	Homologous_superfamily

Pfam: PF13671

UniProt features (8 total): splice variant 4, chain 1, region of interest 1, coiled-coil region 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q92802-F1	55.10	0.25

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 201 (showing top): GOBP_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, BASSO_B_LYMPHOCYTE_NETWORK, GOBP_NEGATIVE_REGULATION_OF_STEM_CELL_DIFFERENTIATION, GARGALOVIC_RESPONSE_TO_OXIDIZED_PHOSPHOLIPIDS_BLUE_UP, chr13q13, YY1_Q6, GOBP_STEM_CELL_PROLIFERATION, GOBP_HEMATOPOIETIC_STEM_CELL_DIFFERENTIATION, GOBP_NEGATIVE_REGULATION_OF_HEMATOPOIETIC_PROGENITOR_CELL_DIFFERENTIATION, LINDSTEDT_DENDRITIC_CELL_MATURATION_B, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN, KOYAMA_SEMA3B_TARGETS_UP, YY1_02

GO Biological Process (5): negative regulation of transcription by RNA polymerase II (GO:0000122), blastocyst development (GO:0001824), positive regulation of hematopoietic stem cell proliferation (GO:1902035), negative regulation of hematopoietic stem cell differentiation (GO:1902037), in utero embryonic development (GO:0001701)

GO Molecular Function (3): transcription corepressor activity (GO:0003714), enzyme binding (GO:0019899), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), transcription repressor complex (GO:0017053), extracellular exosome (GO:0070062), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
negative regulation of DNA-templated transcription	2
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
in utero embryonic development	1
anatomical structure development	1
hematopoietic stem cell proliferation	1
regulation of hematopoietic stem cell proliferation	1
positive regulation of stem cell proliferation	1
hematopoietic stem cell differentiation	1
negative regulation of hematopoietic progenitor cell differentiation	1
regulation of hematopoietic stem cell differentiation	1
negative regulation of stem cell differentiation	1
chordate embryonic development	1
transcription coregulator activity	1
protein binding	1
binding	1
intracellular membrane-bounded organelle	1
transcription regulator complex	1
extracellular vesicle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1229 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
N4BP2L2	EXOC6B	Q9Y2D4	482
N4BP2L2	ZNF805	Q5CZA5	464
N4BP2L2	REPS1	Q96D71	449
N4BP2L2	IRGQ	Q8WZA9	431
N4BP2L2	DPAGT1	Q9H3H5	397
N4BP2L2	KCTD20	Q7Z5Y7	391
N4BP2L2	AATF	Q9NY61	385
N4BP2L2	PRR22	Q8IZ63	372
N4BP2L2	ADPGK	Q9BRR6	358
N4BP2L2	GTF2IRD2B	Q6EKJ0	350
N4BP2L2	GTF2IRD2	Q86UP8	349
N4BP2L2	RUNDC3A	Q59EK9	337
N4BP2L2	SPIRE1	Q08AE8	333
N4BP2L2	ARFIP1	P53367	330
N4BP2L2	RUNDC3B	Q96NL0	327

IntAct

105 interactions, top by confidence:

A	B	Type	Score
PRPF4	PPIH	psi-mi:“MI:0914”(association)	0.910
RFXANK	RFXAP	psi-mi:“MI:0914”(association)	0.780
PPIH	N4BP2L2	psi-mi:“MI:0915”(physical association)	0.720
N4BP2L2	PPIH	psi-mi:“MI:0915”(physical association)	0.720
PRG2	YPEL5	psi-mi:“MI:0914”(association)	0.640
Hoxa1	N4BP2L2	psi-mi:“MI:0915”(physical association)	0.570
LMO2	N4BP2L2	psi-mi:“MI:0915”(physical association)	0.560
N4BP2L2	HOXA1	psi-mi:“MI:0915”(physical association)	0.560
	N4BP2L2	psi-mi:“MI:0915”(physical association)	0.560
NAA38	N4BP2L2	psi-mi:“MI:0915”(physical association)	0.560
HOXA1	N4BP2L2	psi-mi:“MI:0915”(physical association)	0.560
N4BP2L2		psi-mi:“MI:0915”(physical association)	0.560
N4BP2L2	NAA38	psi-mi:“MI:0915”(physical association)	0.560
N4BP2L2	PPIL1	psi-mi:“MI:0915”(physical association)	0.560
MRPS18C	MRPS14	psi-mi:“MI:0914”(association)	0.530
PIP	TBKBP1	psi-mi:“MI:0914”(association)	0.530
N4BP2L2	bipA	psi-mi:“MI:0915”(physical association)	0.370
N4BP2L2	rep	psi-mi:“MI:0915”(physical association)	0.370
N4BP2L2		psi-mi:“MI:0915”(physical association)	0.370
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350

BioGRID (103): N4BP2L2 (Two-hybrid), N4BP2L2 (Two-hybrid), PPIH (Two-hybrid), NAA38 (Two-hybrid), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), Hoxa1 (Affinity Capture-Western), PPIA (Two-hybrid), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS), N4BP2L2 (Affinity Capture-MS)

ESM2 similar proteins: A0A140LFM6, A0A2K1JJ00, A0JMD2, A4H824, A5WWA0, A9ZPC9, B0S6S9, D3ZJ47, H0WFA5, O70343, P15822, P24433, P31629, P48437, Q0P4S0, Q0VAV2, Q15468, Q1LV19, Q1LY84, Q4V7H1, Q5RD08, Q5SWW4, Q60988, Q62417, Q66H65, Q6DFV3, Q6ZPK7, Q71RC2, Q80TY4, Q80U59, Q865B6, Q865B7, Q8JZS6, Q8K3V7, Q8LFU0, Q8VY64, Q91018, Q92786, Q92802, Q93ZL5

Diamond homologs: Q29S05, Q3V2Q8, Q5TBK1, Q66H65, Q86UW6, Q8JZS6, Q92802, P13233, O64843, O74840, Q08954, Q9UTP4

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

42 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	20
Likely benign	4
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
599575	NM_001278432.2(N4BP2L2):c.1406dup (p.Asn469fs)	Pathogenic

SpliceAI

1211 predictions. Top by Δscore:

Variant	Effect	Δscore
13:32517866:C:A	donor_gain	1.0000
13:32521371:A:AC	donor_gain	1.0000
13:32521372:C:CC	donor_gain	1.0000
13:32521372:CTTTT:C	donor_gain	1.0000
13:32522163:T:A	donor_gain	1.0000
13:32522181:CCA:C	donor_gain	1.0000
13:32522186:T:TA	donor_gain	1.0000
13:32522268:TTG:T	acceptor_gain	1.0000
13:32522271:C:CC	acceptor_gain	1.0000
13:32522281:A:C	acceptor_gain	1.0000
13:32527394:AGC:A	donor_gain	1.0000
13:32537025:CAT:C	acceptor_gain	1.0000
13:32521372:CTT:C	donor_gain	0.9900
13:32521448:GCCTA:G	acceptor_loss	0.9900
13:32521449:CCT:C	acceptor_loss	0.9900
13:32522181:C:CT	donor_gain	0.9900
13:32522266:TTTTG:T	acceptor_gain	0.9900
13:32522267:TTTG:T	acceptor_gain	0.9900
13:32522269:TG:T	acceptor_gain	0.9900
13:32522269:TGC:T	acceptor_loss	0.9900
13:32522271:C:T	acceptor_loss	0.9900
13:32522272:T:A	acceptor_loss	0.9900
13:32522281:A:AC	acceptor_gain	0.9900
13:32522283:A:C	acceptor_gain	0.9900
13:32527394:AG:A	donor_gain	0.9900
13:32527395:G:C	donor_gain	0.9900
13:32527531:TT:T	acceptor_gain	0.9900
13:32527533:C:CC	acceptor_gain	0.9900
13:32537026:ATCT:A	acceptor_loss	0.9900
13:32537027:TCTGA:T	acceptor_loss	0.9900

AlphaMissense

3937 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
13:32521399:C:A	W508C	0.999
13:32521399:C:G	W508C	0.999
13:32521401:A:G	W508R	0.999
13:32521401:A:T	W508R	0.999
13:32522206:C:A	W483C	0.999
13:32522206:C:G	W483C	0.999
13:32522208:A:G	W483R	0.999
13:32522208:A:T	W483R	0.999
13:32522224:G:C	N477K	0.999
13:32522224:G:T	N477K	0.999
13:32522228:T:A	D476V	0.999
13:32522231:A:T	I475K	0.999
13:32522234:A:T	I474K	0.999
13:32522237:A:T	V473D	0.999
13:32527478:A:C	F438L	0.999
13:32527478:A:T	F438L	0.999
13:32527479:A:G	F438S	0.999
13:32527480:A:G	F438L	0.999
13:32535784:T:A	K415I	0.999
13:32517962:A:G	M531T	0.998
13:32521379:A:G	L515S	0.998
13:32521412:G:T	P504H	0.998
13:32521420:A:C	F501L	0.998
13:32521420:A:T	F501L	0.998
13:32521421:A:G	F501S	0.998
13:32521422:A:G	F501L	0.998
13:32521448:G:T	A492D	0.998
13:32522218:A:C	N479K	0.998
13:32522218:A:T	N479K	0.998
13:32522229:C:G	D476H	0.998

dbSNP variants (sampled 300 via entrez): RS1000012513 (13:32533947 G>T), RS1000023203 (13:32491377 A>G), RS1000033775 (13:32474407 C>T), RS1000034790 (13:32435189 CT>C), RS1000053451 (13:32484312 G>A,C), RS1000109786 (13:32446287 G>A,C,T), RS1000143571 (13:32517533 A>G), RS1000158592 (13:32534542 TTCA>T), RS1000171200 (13:32456271 C>T), RS1000228527 (13:32464377 A>G), RS1000241441 (13:32506745 A>G), RS1000247237 (13:32501120 G>A), RS1000265854 (13:32514668 G>A), RS1000277887 (13:32477470 C>A), RS1000302628 (13:32500863 TTC>T)

Disease associations

OMIM: gene MIM:615788 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST001937_19	Breast cancer	5.000000e-08
GCST005196_74	Coronary artery disease	7.000000e-11
GCST006612_83	LDL cholesterol	2.000000e-14
GCST006979_1094	Heel bone mineral density	2.000000e-12
GCST007010_2	Logical memory (delayed recall)	1.000000e-06
GCST010866_102	Coronary artery disease	3.000000e-09
GCST010988_464	Adult body size	3.000000e-13
GCST011365_2	Myocardial infarction	4.000000e-08

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0009270	heel bone mineral density
EFO:0004874	memory performance

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression, affects expression, decreases expression, decreases methylation	5
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	3
mercuric bromide	increases expression, affects cotreatment	2
Arsenic	affects cotreatment, increases abundance, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
Aflatoxin B1	decreases methylation	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
testosterone enanthate	affects expression	1
methylmercuric chloride	increases expression, decreases expression	1
trichostatin A	increases expression	1
benzo(e)pyrene	decreases methylation	1
aflatoxin B2	decreases methylation	1
tamibarotene	decreases expression	1
pentabromodiphenyl ether	increases expression	1
JP8 aviation fuel	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
ICG 001	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	increases response to substance, increases expression	1
jinfukang	decreases expression	1
NSC 689534	affects binding, increases expression	1
(+)-JQ1 compound	decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Vorinostat	increases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.